Contact
searchSearch
HMP Global
Login

News

News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology
Conference Coverage
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
Conference Coverage
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
Conference Coverage
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
Conference Coverage
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
Conference Coverage
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology
Conference Coverage
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology
Conference Coverage
First-Line Capecitabine Plus Carboplatin Reduces Neurotoxicity Without Compromising Efficacy in Metastatic HER2-Negative Esophagogastric Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a...
01/08/2026
Oncology
Conference Coverage
First-Line Capecitabine Plus Carboplatin Reduces Neurotoxicity Without Compromising Efficacy in Metastatic HER2-Negative Esophagogastric Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a...
01/08/2026
Oncology
News
Bemarituzumab Added to Chemotherapy Significantly Benefits Survival in FGFR2b-Positive Gastric and GEJ Cancer
10/20/2025
Stephanie Holland
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3...
10/20/2025
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use